Summit Therapeutics Inc.
SMMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001599298
No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Summit Therapeutics Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 206 | 6 | 222 | +22 |
| Shares | 117.8M | 12.6M | 118.9M | +13.7M (+13.0%) |
| Value | $2.06B | $219.5M | $2.25B | +$411.9M (+22.4%) |
6 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (58)
Institutions that held Summit Therapeutics Inc. at the end of Q1 2026 but not at the end of Q4 2025.
Sold out (36)
Institutions that held Summit Therapeutics Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
Not filed for Q1 2026 yet (6)
Institutions that held Summit Therapeutics Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 11,177,220 | $195.5M |
| Norges Bank | 1,373,943 | $24.0M |
| Litman Gregory Asset Management LLC | 50 | $875 |
| ORG Partners LLC | 40 | $699 |
| Comerica Bank | 32 | $560 |
| CIBC Private Wealth Group, LLC | 3 | $52 |